99
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

TSC22D2 Regulates ACOT8 to Delay the Malignant Progression of Colorectal Cancer

, , , , ORCID Icon, ORCID Icon & show all
Pages 171-180 | Received 10 Nov 2023, Accepted 27 Feb 2024, Published online: 04 Mar 2024
 

Abstract

Purpose

Colorectal cancer (CRC) is one of the cancers with high incidence and mortality rates worldwide. In China, there are approximately 400,000 new CRC cases each year, seriously endangering people’s life and health. Transforming growth factor β-stimulated clone 22 domain family, member 2 (TSC22D2) is widely expression in cancers, but the role of TSC22D2 in CRC are still unknown.

Methods

Real‑time quantitative PCR (qRT-PCR) and Western blot were applied to determine the TSC22D2 levels. CCK-8, colony formation and transwell assays were used to determine the proliferation and metastasis abilities of CRC cells in vitro. In vivo metastatic potential was assessed using a subcutaneously injected mouse model and. Western-blot and immunoprecipitation experiments were used to study the mechanism of TSC22D2‑mediated metastasis.

Results

We found TSC22D2 was deregulated in CRC tissues and cells and implied poor prognosis. Overexpression TSC22D2 significantly promoted CRC cells proliferation and tumorigenicity both in vitro and vivo, whereas knockdown TSC22D2 resulted in the opposite effects. Importantly using a co-immunoprecipitation (co-IP) assay combined with mass spectrometry analysis to identify TSC22D2-interacting acyl-coenzyme A thioesterases 8 (ACOT8), TSC22D2 maintained stability of ACOT8. Overexpression of TCC22D2 in CRC cells can promote the expression of ACOT8 and inhibit the proliferation and metastasis of CRC cells through EMT mechanism, highlighting the possibility of TSC22D2 as a potential target in CRC development.

Conclusion

In summary, the present study revealed the inhibitory effect of TSC22D2 on the proliferation of colorectal cancer cells, suggesting that TSC22D2 may be an important tumor suppressor and a potential therapeutic target during colorectal carcinogenesis.

Institutional Board Statement

The animal study protocol followed the Guide for the Care and Use of Laboratory Animals and was approved by the Zhejiang Provincial Animal Care and Use Committee. (Ethics Code: ZJCLA-IACUC-20040166).

Disclosure

The authors report no competing interests in this work.

Additional information

Funding

This study was supported by the Health Department of Zhejiang Province (NO.2021KY646).